18F-FDG uptake of brown fat and cancer: casualty or causality? Nicolò GennaroGiovanna PepeLidija Antunovic Letter to the Editor 08 March 2019 Pages: 1395 - 1396
Breaking an unhelpful circle, where innovation and regularia delay clinical practice for patient benefit Peter EllIgnasi CarrioArturo Chiti Editorial 03 April 2019 Pages: 1397 - 1398
Endorsement of International Consensus Radiochemistry Nomenclature Guidelines Philip ElsingaAngelika Bischof DelaloyeIgnasi Carrio Editorial 16 April 2019 Pages: 1399 - 1399
EANM Focus 1: one small step for two men, one giant leap for a specialty Stefano FantiWim J. G. Oyen Editorial 24 April 2019 Pages: 1400 - 1401
Time for new imaging and therapeutic approaches in cardiac amyloidosis Riemer H. J. A. SlartAndor W. J. M. GlaudemansHans L. A. Nienhuis Editorial Commentary 23 April 2019 Pages: 1402 - 1406
Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy Malte KircherSandra IhneConstantin Lapa Original Article 23 February 2019 Pages: 1407 - 1416
Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI Qaid Ahmed ShageraGi Jeong CheonJune-Key Chung Original Article 02 April 2019 Pages: 1417 - 1427
TSH suppression aggravates arterial inflammation — an 18F-FDG PET study in thyroid carcinoma patients Ellen BoswijkKarin J. C. SandersJan Bucerius Original Article Open access 11 March 2019 Pages: 1428 - 1438
Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial Maja GuberinaWilfried EberhardtChristoph Pöttgen Original Article 01 February 2019 Pages: 1439 - 1447
Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up] Pierre VeraSorina-Dana Mihailescuall investigators of RTEP5 study (list in annexe) Original Article 13 March 2019 Pages: 1448 - 1456
Development and validation of the PET-CT score for diagnosis of malignant pleural effusion Min-Fu YangZhao-Hui TongHuan-Zhong Shi Original Article Open access 22 March 2019 Pages: 1457 - 1467
PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy Lidija AntunovicRita De SanctisMartina Sollini Original Article 26 March 2019 Pages: 1468 - 1477
Exploratory radiomic features from integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer Serena BaioccoBert-Ram SahVicky Goh Original Article Open access 27 March 2019 Pages: 1478 - 1484
Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma Frank HofheinzYimin LiSebastian Zschaeck Original Article 04 April 2019 Pages: 1485 - 1494
Perioperative PET/CT lymphoscintigraphy and fluorescent real-time imaging for sentinel lymph node mapping in early staged colon cancer M. AnkersmitO. S. HoekstraW. J. H. J. Meijerink Original Article Open access 23 February 2019 Pages: 1495 - 1505
Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization Kostas DelaunayJulien EdelineEtienne Garin Original Article 04 February 2019 Pages: 1506 - 1517
18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer Akira ToriiharaHeying DuanAndrei Iagaru Short Communication 08 March 2019 Pages: 1518 - 1523
Clinical utility of 68Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma Yuji NakamotoTakayoshi IshimoriKaori Togashi Original Article 07 March 2019 Pages: 1524 - 1530
Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections Jie GaoChengwei ZhangHongqian Guo Original Article 25 April 2019 Pages: 1531 - 1541
Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy Lino M. SawickiJulian KirchnerHubertus Hautzel Original Article 16 March 2019 Pages: 1542 - 1550
Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring? Marie VoglimacciErwan GabiacheAlejandra Martinez Original Article 07 February 2019 Pages: 1551 - 1559
Adrenal tracer uptake by 18F-FDOPA PET/CT in patients with pheochromocytoma and controls Walter NoordzijAndor W. J. M. GlaudemansMichiel N. Kerstens Original Article Open access 22 April 2019 Pages: 1560 - 1566
Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma Jose GenollaTrinidad RodriguezAizpea Echebarria Original Article 05 March 2019 Pages: 1567 - 1575
Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment Larissa Bastos CostaMarcelo Araujo QueirozCarlos Alberto Buchpiguel Image of the Month 22 April 2019 Pages: 1576 - 1577
One-stop shopping 18F-FDG PET/CT in a patient with vascular type Behçet’s disease Takashi NorikaneYuka YamamotoYoshihiro Nishiyama Image of the Month 12 March 2019 Pages: 1578 - 1580
Correction to: 18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions Olivier HumbertVéronique BourgJacques Darcourt Correction 13 April 2019 Pages: 1581 - 1581